These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38356106)

  • 21. Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association.
    Alharbi AS; Alzahrani M; Alodayani AN; Alhindi MY; Alharbi S; Alnemri A
    Saudi Med J; 2021 Apr; 42(4):355-362. PubMed ID: 33795490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
    Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
    [No Abstract]   [Full Text] [Related]  

  • 25. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
    Ginsberg GM; Somekh E; Schlesinger Y
    Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE; Huertas VM
    BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries.
    Simões EA; Carbonell-Estrany X; Guilbert T; Mansbach JM; Piedra PA; Ramilo O; Welliver R
    Pediatr Infect Dis J; 2015 Oct; 34(10):1086-92. PubMed ID: 26121204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
    Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
    Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
    Kurai D; Mizukami A; Preckler V; Verelst F; Molnar D; Matsuki T; Ho Y; Igarashi A
    Expert Rev Vaccines; 2024; 23(1):303-311. PubMed ID: 38426479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
    Mochizuki H; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
    Am J Respir Crit Care Med; 2017 Jul; 196(1):29-38. PubMed ID: 28152315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
    Ezpeleta G; Navascués A; Viguria N; Herranz-Aguirre M; Juan Belloc SE; Gimeno Ballester J; Muruzábal JC; García-Cenoz M; Trobajo-Sanmartín C; Echeverria A; Martínez-Baz I; Vera-Punzano N; Casado I; López-Mendoza H; Ezpeleta C; Castilla J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.